96 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author민경환-
dc.date.accessioned2019-11-24T18:50:43Z-
dc.date.available2019-11-24T18:50:43Z-
dc.date.issued2017-04-
dc.identifier.citationPATHOLOGY RESEARCH AND PRACTICE, v. 213, no. 4, page. 381-388en_US
dc.identifier.issn0344-0338-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0344033816302667?via%3Dihub-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/113857-
dc.description.abstractHepatocyte growth factor (HGF) and MET are candidates of targeted therapies for cancer patients. Although MET and HGF are commonly expressed in biliary tract cancers, their expression and gene copy number status and their association with KRAS mutations have not been investigated in pancreatobiliary-type ampullary adenocarcinomas (A-ACs), one of the aggressive periampullary cancers. MET and HGF expressions and MET copy number status were examined by performing immunohistochemistry (IHC) and silver in situ hybridization (SISH) in 62 surgically resected, paraffin-embedded tumors, respectively. High MET and HGF protein expressions were detected in 24 (38.7%) and 15 (24.2%) tumors. High MET expression was associated with KRAS mutation. However, there were no associations of high MET/HGF expression alone with other clinicopathological feature or survival. MET SISH positivity was detected in 19 tumors (30.6%), where 84.2% were due to high trisomy or polysomy and only 3 cases (15.8%) were MET gene amplification. The overall MET protein overexpression was well correlated with METSISH positivity. The concurrent MET SISH positivity and KRAS mutation, not each alone, was an independent poor prognostic factor of disease-free survival only in pancreatobiliary subtype of A-ACs, but not in intestinal subtype.Concurrent MET SISH positivity and KRAS mutation may predict a high risk of recurrence in pancreatobiliary subtype of A-ACs, indicating those markers could be potent candidates for a new therapeutic target in this cancer type. MET IHC can be used as a reliable tool screening for MET copy number status in ampullary cancers. (C) 2017 Elsevier GmbH. All rights reserved.en_US
dc.description.sponsorshipThis research was supported by Hallym University Research Funds (HURF-2015-08) and (HURF-2016-40) and by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2016R1D1A1B03935447).en_US
dc.language.isoen_USen_US
dc.publisherELSEVIER GMBHen_US
dc.subjectAmpulla of Vateren_US
dc.subjectAdenocarcinomaen_US
dc.subjectMETen_US
dc.subjectHGFen_US
dc.subjectImmunohistochemistryen_US
dc.subjectSilver in situ hybridizationen_US
dc.titleConcurrent MET copy number gain and KRAS mutation is a poor prognostic factor in pancreatobiliary subtype ampullary cancersen_US
dc.typeArticleen_US
dc.relation.no4-
dc.relation.volume213-
dc.identifier.doi10.1016/j.prp.2017.01.004-
dc.relation.page381-388-
dc.relation.journalPATHOLOGY RESEARCH AND PRACTICE-
dc.contributor.googleauthorKwon, Mi Jung-
dc.contributor.googleauthorKim, Jeong Won-
dc.contributor.googleauthorJeon, Jang Yong-
dc.contributor.googleauthorNam, Eun Sook-
dc.contributor.googleauthorCho, Seong Jin-
dc.contributor.googleauthorPark, Hye-Rim-
dc.contributor.googleauthorMin, Soo Kee-
dc.contributor.googleauthorSeo, Jinwon-
dc.contributor.googleauthorMin, Kyueng-Whan-
dc.contributor.googleauthorChoe, Ji-Young-
dc.relation.code2017003229-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidkyueng-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE